SynAct Pharma is a clinical stage biotechnology company that is harnessing melanocortin biology to help the body resolve excessive or chronic inflammation
- Inflammation is the immune system’s way of responding to infections or injuries. Normally an inflammatory response is self-limiting. The immune system will “deactivate” itself and the inflammation will be resolved after the invading pathogen has been removed or the injury has begun to heal.
- However, in some cases, the inflammation can be excessive or chronic and it can overwhelm the immune system’s ability to resolve the inflammation. This can lead to pain, tissue destruction, and loss of function.
When the immune system is overwhelmed, therapies like AP1189 may help resolve inflammation by providing both anti-inflammatory activity and by triggering the immune system’s natural inflammatory resolution mechanisms.